Gibson Dunn Advised Shareholders in Connection with Sale of Aicuris to Asahi Kasei

Through its company Veloxis Pharmaceuticals, Inc., Gibson Dunn provided advice to the shareholders for the sale of Aicuris Anti-infective Cures AG to Asahi Kasei. The purchase price is 780 million euros, or roughly $920 million USD.